Compare First Citizens BancShares Inc (FCNCA) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Repligen Corporation Common Stock — how do they compare? First Citizens BancShares Inc trades at $2,052.8 (market cap $23.01B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: First Citizens BancShares Inc is far larger — about 2.1× Repligen Corporation Common Stock's market cap, and First Citizens BancShares Inc pays a 0.4% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 30 Days and Repligen Corporation Common Stock for 0 Days on average.
| FCNCA | RGEN | |
|---|---|---|
Market Cap | $23.01B | $11.14B |
Volume | 64,069 | 1,259,263 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $194.57 |
52-Week Low | $1.64K | $102.87 |
Typical Hold Time | 30 Days | 0 Days |
Dividend Yield | 0.4% | — |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCNCA trades at $2,075.12, down 0.35% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $57.09 per share, beating estimates, and maintains a net income margin of 25.23%. Recent news includes a $157 million financing deal and branch expansion initiatives, signaling growth. Cash flow improved to a net positive $630 million in 2026 from a slight deficit in 2025.
The outlook is mixed: solid profitability and earnings beats support upside toward the $2,290 consensus price target, but technical bearishness and high institutional hold ratings suggest near-term caution. Key risks include execution of expansion and interest rate sensitivity. The stock offers value with a P/E of 11.13, yet requires monitoring of technical levels for entry.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
